ArticleScientific reports2026
Development of a green chemistry based bioanalytical method using response surface methodology to analyze febuxostat and indomethacin in rabbit plasma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research established an environmentally friendly and sustainable approach to measure Febuxostat and Indomethacin levels in rabbit plasma samples, utilizing isocratic liquid chromatography guided by green analytical chemistry principles and Analytical Quality by Design (AQbD) methodology. Chromatographic separation was performed on an Eclipse Plus C18 column (25 cm x 5 cm,4.6 μm), using a binary mobile phase of ethanol and 50 mM potassium dihydrogen orthophosphate (pH 4.5) in a 66:34 ratio, delivered at 0.8 mL/min for 15 min. Resolution and asymmetry factors were designated Critical Analytical Attributes (CAAs). Control Noise Experimentation (CNX) screening identified flow rate, mobile phase pH, and ethanol concentration as significant contributors to CAAs variability. Subsequent optimization utilizing Central Composite Design (CCD) refined the Critical Method Parameters (CMPs) to ensure optimal performance. Chromatographic analysis revealed Febuxostat and Indomethacin retention times of 4.41 and 7.35 min, respectively. The method’s greenness and analytical quality were assessed using AGREE, ComplexGAPI, RGB, and AMGS tools. Validation studies confirmed linearity (R2: 0.9959 for Febuxostat, 0.9981 for Indomethacin) within 200–4600 ng/mL, alongside successful precision, accuracy, recovery, and stability evaluations at concentrations of 250, 750, 1500, and 3000 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.